

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 April 2011 (21.04.2011)

PCT

(10) International Publication Number  
**WO 2011/046504 A1**

- (51) **International Patent Classification:**  
A61M 1/34 (2006.01) A61M 1/38 (2006.01)
- (21) **International Application Number:**  
PCT/SE2010/051124
- (22) **International Filing Date:**  
18 October 2010 (18.10.2010)
- (25) **Filing Language:** Swedish
- (26) **Publication Language:** English
- (30) **Priority Data:**  
0901341-8 18 October 2009 (18.10.2009) SE
- (71) **Applicant (for all designated States except US):** GLY-COREX AB [SE/SE]; Sölvegatan 41, S-223 70 Lund (SE).
- (72) **Inventor; and**
- (75) **Inventor/Applicant (for US only):** NILSSON, Kurt ,G., I. [SE/SE]; Andjaktsvägen 6, S-226 53 Lund (SE).
- (74) **Agent:** AWAPATENT AB; Jeanette Jakobsson, Box 5117, S-200 71 Malmö (SE).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report (Art. 21(3))

(54) **Title:** METHOD AND PRODUCT FOR BLOOD TREATMENT AND PURIFICATION



(57) **Abstract:** Extracorporeal blood treatment is performed daily on a large number of patients by use of for example a dialysis filter, plasma filter or a centrifuge. The purpose of the treatment is to separate minor components and molecules in a liquid or in the blood from larger ones, for example in connection with different disease conditions or with a view to extracting blood plasma, target substances such as blood components or molecules from for example blood donors. According to the present invention two separation steps are used together with a solution or a suspension containing at least one component, which specifically may bind to the component or the blood component to be specifically reduced, or to be refined/extracted during the treatment or during the blood treatment.

WO 2011/046504 A1

Method and Product for Blood Treatment and Purification

**Extracorporeal blood treatment is performed daily on a large number of patients, e.g. by use of a dialysis filter, a plasma filter or a centrifuge.**

**The purpose of the treatment is to separate smaller components and molecules from larger ones in the blood in connection with different disease conditions or to extract blood plasma, target substances such as blood components or molecules from blood donors.**

**In dialysis, plasma exchange (therapeutic plasma exchange, TPE) or double filter treatments (DFPP, filters having different pore size for each treatment are used.**

**In dialysis filters allowing passage of relatively small molecules (normally less than 67,000 in molecular weight) are used. In plasma exchange blood filters (unless a centrifugation method is used) having a larger pore size allowing passage of all plasma components in the blood except red blood cells and white blood cells are used. In the case of DFPP two filters are used, one "coarse" filter of the same type that is used in plasma exchange and a filter having a smaller pore size separating plasma components depending on size.**

**Thus, all of the above-mentioned methods make possible a separation based on molecular weight and size of the different blood components. However, these methods do not give any biospecific separation, i.e. based on the biological specificity of each blood component.**

**Therefore, an approach called immunospecific blood treatment (IA) has been introduced, wherein a biospecific column is used during the treatment.**

**IA makes possible a specific treatment, i.e. specific elimination or reduction of a target substance during the treatment, e.g. immunoglobulin G, from other**

proteins in the blood, but also separation from proteins having a similar molecular weight/size as immunoglobulin G.

5 Columns containing protein A are examples of these. These columns contain covalently bound protein A. Other examples are immunoglobulin-based columns for specific elimination of immunoglobulins or for separation of other proteins from plasma. Other examples are columns having a covalently bound blood group antigen with a view to specifically binding that part of antibodies in the blood which is specific for the blood group determinants A and B, respectively, while other antibodies and other blood components pass through the column.

15 In IA a plasma filter (like in PE) or a centrifuge is normally used, which continuously separates the plasma from the blood cells, and the plasma is transported through a tube to a column in which the target protein/substance is bound and thereby is specifically separated from other plasma components. Blood plasma which has passed through the column is transported back to the patient.

20 Thus, the IA treatment takes place in a system having two circuits, one blood conduit leading away from and back to the patient with separated blood cells after the plasma filter and a plasma conduit containing the IA column after the plasma filter. The two conduits are connected before the return to the patient, and the treatment is continuous.

25 The problem with the above-mentioned IA column treatment is that several columns having different geometry and methods of production have to be designed for the different specific treatments and that several types of columns, e.g. protein A and immunoglobulin columns, become saturated and have to be regenerated during the treatment. The flow rate through the column is often a limiting factor and prolongs the treatment time. The size of the patients and different degrees of abnormality to be treated make treat-

ment with a column troublesome in view of the adaption of the treatment to the patient.

5 A problem with the physical size-dependent PE and DFPP treatments is that they are not specific and that they, in addition to the target substance/target substances, also eliminate a large number of other important components in the blood. This creates undesired side effects, e.g. not only antibodies are eliminated, but also a large quantity of other important blood components in DFPP. Replacement liquids containing e.g. albumin, IVIG injections for the  
10 replacement of immunoglobulins, and coagulation factors pass through the column and have to be replaced.

The present invention discloses a product and a method in which these drawbacks are avoided or minimized.

15

In the present invention two separation steps are used together with a solution or a suspension containing at least one component which has the ability to specifically bind to the component or blood component to be specifically reduced or to be refined/extracted during the treatment or during the blood  
20 treatment.

In one example of an embodiment of the present invention the two separation steps are performed by use of two coarse filters. The term coarse filter is here intended to mean a filter of the same or similar type which normally is used in  
25 PE and having pores which allow the passage of plasma but not of red and white blood cells. In an another embodiment according to the present invention one coarse filter and one filter having a smaller pore size than the coarse filter are used.

30 The component (called the Component below) used according to the present invention to specifically bind to the target component/substance that is to be reduced in the blood is soluble or forms a suspension in the buffer used during the treatment.

According to the present invention the treatment is performed in two connect-  
ed steps. In step 1 blood cells are separated, for example, from plasma with a  
coarse filter or a centrifuge, and in step 2 the separated blood plasma is  
5 transported onwards and is mixed with the Component binding the target  
components/substance, and in the subsequent blood filter the plasma is  
separated from the Component having a bound target substance (antibody,  
protein, virus, bacterium, bacteria component, cell). The plasma is then  
returned to the patient, like in IA and DFPP.

10

The separation of the Component and the Component having a target sub-  
stance/component bound thereto takes place because these cannot pass  
through the filter in step 2, in contrast to the plasma. The treated plasma  
having a reduced content of the target substance/component to be reduced is  
15 recirculated to the patient via the blood conduit.

The treatment may be performed continuously or with interruptions with a  
view to washing the second filter from the Component having a target sub-  
stance/component bound thereto. The solution involving the Component may  
20 continuously be transported to a "waste bag" during the treatment or be con-  
tinuously returned to the second filter. This, as well as the chosen pore size,  
the apparatus (there is a large number of commercially available filters, as  
well as different centrifuges and machines for plasma treatments) are deter-  
mined by the person skilled in the art, as well as the flow rates, the amount of  
25 the Component, the treatment period, the temperature and the pressure in the  
different blood and plasma conduits during the treatment, as well as other  
parameters. Thus, this does not limit the scope of the present invention.

In this way several of the advantages associated with IA and DFPP are  
30 obtained, and at the same time several of the disadvantages encountered  
when using the IA and DFPP method, respectively, are avoided.

The Component according to the present invention consists of at least two partial components, i.e. one matrix and one ligand. The matrix may for example be built up by dextran, polyethyleneglycol or another substance or polymer which is soluble in the aqueous buffer (e.g. PA buffer or saline buffer) which is used with a view to dissolving the Component. The Component contains at least one covalently bound ligand, e.g. biotin or another biomolecule having affinity to another biomolecule, virus, bacterium, bacterium component or cell, such as a peptide, protein, immunoglobuline, enzyme, saccharide (mono-, di-, tri-, tetra-, penta-, hexasaccharide or higher saccharide).

The matrix may also consist of a non-soluble polymer, e.g. consisting of a plastic or a polymer or a polysaccharide. There are several examples thereof having several configurations and these do not limit the scope of invention. As non-limiting examples cross-linked agarose in the form of porous microparticles, also commercially available as e.g. Sepharose, could be mentioned. Several variants of this exist and do not limit the scope of invention. The amount, the pore size and the size of the matrix, e.g. in the form of microspheres or microparticles, do not limit the scope of invention. A typical size of the matrix is from 1 micrometer up to 300 micrometers in particle size and any average size of the particles within this interval.

The molecular size of the dextran, the polyethylene glycol and any other soluble substance may be chosen by the person skilled in the art. Typical sizes are any size within the interval from 100,000 to 1 million Daltons. The size of the matrix is chosen, inter alia, with regard to the capacity and the fact that the second filter used according to the present invention should not allow passage of the matrix, wherein the treated plasma returned to the patient does not contain the matrix and not the matrix having the target substance/-component bound thereto.

The ligand is covalently bound to the matrix. This can take place by use of one or more methods chosen by a person skilled in the art from a large

number of different methods. This does not limit the scope of the present invention. Non-limiting methods, e.g. the NHS, EDC, epoxy, CNBr, tosyl, tresyl method, and a di-, tri-, tetra- etc, functional cross-linker etc, may be used. Examples of bonds between the ligand and the matrix are for example  
5 an amide bond between the ligand and the matrix, isourea, C-S binding, C-N binding, etc. The ligand may be provided with a so-called spacer with a view to distancing the matrix from the ligand, and the choice of this does not limit the scope of the present invention.

10 The Component may also contain covalently bound biotin which may be used with a view to binding avidin or streptavidin, to which the desired ligand (protein A, another protein, antibody, saccharide) thereafter have been covalently bound, e.g. with EDC, NHS, or a cross-linker. In this way the biotin  
15 matrix may be used for several different target substances/components that are to be reduced in blood.

A figure representing the treatment according to the invention is schematically shown as a non-limiting example in Figure 1.

20 Several variants of the configuration above may be used according to the present invention and do not limit the scope thereof. The plasma filter may be replaced by a centrifuge, as well as the filter in step 2 above. The P represents pressure gauges. The Component with the ligand may be added continuously or at the beginning of the treatment. The Component with the  
25 ligand may be returned to the plasma conduit after passing through filter 2 (according to 2A above) or be transported to a so-called waste bag (according to 2B above), or be collected after the treatment above with a view to refining the target substance, in this case the substance to be extracted. In the latter case the target substance may be eluted from the Component, e.g.  
30 by a change of the pH, wherein for example antibodies and/or proteins are eluted from the Component with a glycine buffer as a non-limiting example, e.g. 0.1 M, pH 2.2 or another desired buffer, concentration, and pH chosen by the person skilled in the art for the specific target substance.

The patient in the scheme above may be replaced by blood donor plasma or another liquid containing the substance to be refined or eliminated from the liquid. In this case the blood donor plasma or said another liquid is treated according to step 1 and step 2 above. The plasma or the liquid may be collected with a reduced amount of the target substance. Alternatively, the target substance may be collected after the elution from the Component.

As a non-limiting example, the blood donor plasma treatment may then be used with a view to providing a plasma which for example is free from, or has a reduced amount of, for example blood group specific antibodies (if the Component contains blood group antigen). Alternatively, as a non-limiting example, antibodies or proteins may be eluted from the Component after the treatment and may be collected.

Non-limiting examples of the Component have been disclosed above. As mentioned above, the Component may contain, as a non-limiting example, a covalently bound saccharide, an antibody, or another protein, but may also, as a non-limiting example, contain a covalently bound positively or negatively charged molecule, e.g. a molecule containing an amine or a carboxyl group, a hydrophobic organic molecule, e.g. an aliphatic or aromatic organic molecule, or e.g. a receptor substance, an amino acid, e.g. tryptophan or a monomeric, oligomeric, or polymeric derivative thereof, or a peptid or a monomeric, oligomeric, or polymeric derivative thereof.

The Component may also consist of a polymer which has been produced in a polymerisation of monomers in the presence of the target substance which is to be refined or isolated, e.g. a drug substance or an environmental toxin, or a degradation product. After washing the produced polymer, this is washed free from the target substance. The resulting so-called imprinted polymer may according to the present invention then be used for isolating of the target substance or refining of the target substance from the treated liquid. According to the invention a coarse filtration of the liquid is made in such a way in step 1.

Non-limiting examples of a saccharide which may be covalently bound to the matrix in the component are mono-, di-, tri-, tetra-, penta- or higher oligo-  
 5 saccharides or oligosaccharide derivatives, which may be monomeric, dimeric or oligomeric derivatives of the saccharide. Examples of monosaccharide units which may be present in the saccharide are one or more of D-galactose, D-mannose, D-glucose, N-acetyl-D-galactosamine, L-fucose, N-acetyl-D-glucosamine, N-acetylneuramic acid, below abbreviated as Gal, Man, Glc, GalNAc, Fuc, GlcNAc, and Sia, respectively.

10

Non-limiting examples are saccharides containing one of or a combination of at least two of the blood group sequences for blood group A, for example

GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-,  
 15 GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-3GalNAc $\beta$   
 GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-3GlcNAc  
 GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-4GlcNAc

Other non-limiting examples are saccharides containing any one or a combination of at least two of the blood group sequences for blood group B, for  
 20 example

Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-,  
 Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-3GalNAc $\beta$   
 25 Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-3GlcNAc  
 Gal $\alpha$ 1-3(Fuc $\alpha$ 1-2)Gal $\beta$ 1-4GlcNAc

Other non-limiting examples are saccharides containing any one or a combination of at least two of the blood group sequences for blood group H, for  
 30 example

Fuc $\alpha$ 1-2Gal $\beta$ 1-,  
 Fuc $\alpha$ 1-2Gal $\beta$ 1-3GalNAc $\beta$

Fuc $\alpha$ 1-2Gal $\beta$ 1-3GlcNAc

Fuc $\alpha$ 1-2Gal $\beta$ 1-4GlcNAc

The saccharide may be present in the form of a monomeric or oligomeric  
5 derivative bound via an aglycon to the matrix forming the Component. A non-  
limiting example thereof is the blood group A derivative GalNAc $\alpha$ 1-3(Fuc $\alpha$ 1-  
2)Gal $\beta$ 1-O-(CH<sub>2</sub>)<sub>2</sub>PhNH covalently bound to a carbonyl group (C=O) on the  
matrix forming an amide bond. The amide bond may be obtained via a so-  
called EDC/NHS reaction, in which a carboxylic group on the matrix is  
10 activated and thereafter is brought to react with the saccharide derivative,  
constituting a non-limiting example of the Component.

In the same way an antibody or another protein, for example, may be bound  
to the matrix.

15

The matrix may for example consist of cross-linked or non-cross-linked  
agarose. This form of the matrix is commercially available for example as the  
trade name Sepharose in different variants in view of cross-linking and con-  
centration, e.g. Sepharose 4FF, 2B, 4B or CL 2B, CL 4B or 6B.

20

Other non-limiting examples of saccharides are lactosamine, Gal $\beta$ 1-  
4GlcNAc $\beta$ 1-3Gal $\beta$ 1-4GlcNAc, saccharides containing GlcNAc, against which  
anti-GlcNAc specific antibodies are formed, blood group P<sub>1</sub>, blood group P<sup>k</sup>,  
Lewis blood group substances, gangliosides, such as GM<sub>1</sub>, GM<sub>2</sub>, Gd<sub>1</sub>, Gd<sub>2</sub>,  
25 other sialylated saccharides, sulfated saccharides and glucuronic acid-  
containing saccharides.

The treatment according to the present invention with the Component con-  
taining blood group A and/or B saccharide(s) may be used for the treatment  
30 of a patient before or in connection with a so-called blood group compatible  
transplantation, e.g. in transplantation of organs or stem cells from donors  
belonging to blood group A, AB or B to recipients belonging to blood group O,  
with a view to specifically eliminating/reducing anti-A; Anti-A and anti-B; and

anti-B antibodies, respectively, binding to the A and B saccharide, respectively, in the Component.

5 The treatment can also be used with a view to extracting the above-mentioned anti-A and/or anti-B antibodies from blood donor plasma or with a view to producing a blood donor plasma without said anti-A and/or anti-B antibodies, or in a reduced amount.

10 Antibodies from blood donor plasma is today extracted for therapeutic purposes, such as intravenous immunoglobuline (IVIG). The present invention may be used for the production of IVIG having a reduced amount of anti-A and/or anti-B antibodies, wherein IVIG, or during the production of IVIG blood donor plasma or protein or the antibody fraction, is treated by use of the method according to the present invention and the component containing A-  
15 and/or B-saccharide.

Antibodies active against pathogenic bacteria or viruses may for example also be extracted from for example blood donor plasma by use of a method according to the present invention. In connection therewith, the component  
20 containing for example any one of the blood group determinants A, B, GlcNAc-containing saccharide or any other saccharide can be used.

Antibodies against Gala1-3Gal saccharides may be extracted in the same way from for example blood donor plasma according to the present invention  
25 with the Component containing a Gala1-3Gal saccharide sequence.

In the same way treatments for other applications, e.g. certain autoimmune diseases, e.g. Guillain-Barré syndrome, myasthenia gravis, may be performed according to the present invention, wherein the Component contains other  
30 of the saccharides exemplified above. The saccharides in the Component are chosen by the person skilled in the art and do not limit the scope of the present invention.

In connection with certain autoimmune diseases, for example protein A or antibody, or other types of protein, amino acid, or peptide containing columns for reduction of antibodies/proteins are used.

- 5 The present invention refers to an alternative treatment according to steps 1 and 2 in the figure above, with a Component containing protein A or antibody, or other types of protein, amino acid, or peptide bound to the matrix.

10 The exact conditions in each application of the present invention is chosen by the person skilled in the art for the specific case, e.g. the size of filter 1 and 2, the initiation/start of the treatment, the flow – treated volume/min, temperature, treatment period, amount of component per treatment. A different amount of the component may be chosen, for example, in the treatment of different patients depending on the patient's size and antibody titres (titer of  
15 e.g. anti-A/anti-B antibodies). The amount of the component per patient treatment may e.g. be from 1 ml and up to 100 ml, or any amount therebetween. The time period may e.g. be from 10 minutes up to e.g. 4 hours or any time period therebetween, which is decided from case to case by the person skilled in the art.

20


Anti-coagulation liquid in the treatment of for example a patient or blood, the flow rates and other treatment parameters may be chosen by the person skilled in the art to be similar/corresponding to those used in DFPP. One of the differences is, as mentioned above, that the patient regains his plasma  
25 substantially intact by use of the present invention, in contrast to the previous accessible treatment, PE or DFPP.

The Component may be delivered to the user in sterile form. The Component may be present, for example, in a sterile packaged form. The sterilization of  
30 the Component may be performed, for example, in connection with for example a GMP production, by autoclavation of saccharide-containing Components.

## CLAIMS

- 5           1. A product and method for treatment or purification, containing at least two filters, or one filter and one centrifuge, or two centrifuges, and one component which in turn contains at least one substance having the ability to bind to a target substance.
- 10           2. The product and method according to claim 1, wherein the substance shows some form of biospecific affinity to the target substance.
- 15           3. The product and method for blood treatment or purification containing at least two filters, or one filter and one centrifuge, or two centrifuges, and one component which in turn contains at least one substance having the ability to bind to or having biospecific affinity to a target substance.
- 20           4. The product and method according to any one of the preceding claims, wherein the target substance is a protein or an antibody.
- 25           5. The product and method for blood treatment or purification containing at least two plasma filters, or one plasma filter and one centrifuge, or two centrifuges, and a component, which in turn contains at least one substance having biospecific affinity to a target substance.
- 30           6. The product and method for blood treatment or purification containing at least two plasma filters, or one filter and one centrifuge, or two centrifuges, and a component which in turn contains at least one saccharide having biospecific affinity to an antibody or to a protein.
7. The product and method for blood treatment or purification containing at least two filters, or one filter and one centrifuge, or two centrifuges, and a component which in turn contains at least one blood group determinant A or B saccharide.

- 5 8. The product and method for blood treatment or purification containing at least two filters, or one filter and one centrifuge, or two centrifuges, and a component which in turn contains at least one substance having biospecific affinity to a target substance, wherein blood or blood plasma having a reduced amount of the target substance is obtained and/or wherein the target substance is extracted.
- 10 9. The product and method for blood treatment or purification containing at least two filters, or one filter and one centrifuge, or two centrifuges, and a component which in turn contains at least one substance or polymer having a specific affinity to a target substance.
- 15 10. Plasma or blood component produced according to claim 1 or any one of the preceding claims.



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE2010/051124

## A. CLASSIFICATION OF SUBJECT MATTER

IPC: see extra sheet

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: A61M, B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2009086203 A2 (AETHLON MEDICAL, INC.), 9 July 2009 (09.07.2009), paragraphs (0047)-(0050) --	1-10
X	EP 1219639 A1 (TORAY INDUSTRIES, INC.), 8 Sept 2000 (08.09.2000), claim 8, paragraphs (0028),(0036),(0039)-(0041) --	1-10
X	US 6746607 B1 (VIJAYALAKSHMI ET AL), 8 June 2004 (08.06.2004), whole document --	1-10
X	US 4770774 A (IDA ET AL), 13 Sept 1988 (13.09.1988), column 2, line 20 - line 62; column 3, line 12 - line 54 --	1-10

 Further documents are listed in the continuation of Box C. See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

25 January 2011

Date of mailing of the international search report

28-01-2011

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Lisa Sellgren / JA A

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No. PCT/SE2010/051124
--

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2006094467 A1 (GUANGZHOU BOPU BIOTECHNOLOGY INC. ET AL), 14 Sept 2006 (14.09.2006), whole document  --	1-10
A	US 4678566 A (WATANABE ET AL), 7 July 1987 (07.07.1987), whole document  -- -----	1-10

**International patent classification (IPC)**

**A61M 1/34** (2006.01)

**A61M 1/38** (2006.01)

**Download your patent documents at [www.prv.se](http://www.prv.se)**

The cited patent documents can be downloaded:

- From "Cited documents" found under our online services at [www.prv.se](http://www.prv.se) (English version)
- From "Anförda dokument" found under "e-tjänster" at [www.prv.se](http://www.prv.se) (Swedish version)

Use the application number as username. The password is **EFXAXBLJLI**.

Paper copies can be ordered at a cost of 50 SEK per copy from PRV InterPat (telephone number 08-782 28 85).

Cited literature, if any, will be enclosed in paper form.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE2010/051124

WO	2009086203	A2	09/07/2009	NONE			
EP	1219639	A1	08/09/2000	WO	0118060	A	15/03/2001
US	6746607	B1	08/06/2004	AT	231411	T	15/02/2003
				AU	6347499	A	22/05/2000
				DE	1124633	T	07/02/2002
				DE	69905066	D,T	22/01/2004
				EP	1124633	A,B	22/01/2003
				SE	1124633	T3	
				ES	2164041	T	16/08/2003
				FR	2785200	A,B	30/03/2001
				JP	2002528242	T	03/09/2002
				WO	0025911	A	11/05/2000
US	4770774	A	13/09/1988	EP	0236509	A,B	10/02/1993
				SE	0236509	T3	
				WO	8701597	A	26/04/1987
WO	2006094467	A1	14/09/2006	CN	1830495	A	13/09/2006
US	4678566	A	07/07/1987	DE	3586832	D,T	01/04/1993
				DE	3587888	D,T	23/02/1995
				DE	3587989	D,T	24/08/1995
				EP	0168801	A,B	19/11/1992
				US	4774019	A	27/09/1988